Greyverse is the trade name for a cosmetic ingredient related to research into hair pigmentation. The manufacturer’s current documentation describes it as a mixture of glycerin and water containing palmitoyl tetrapeptide-20 amide. In scientific publications, the shorter name palmitoyl tetrapeptide-20, or PTP20, is often used. Available evidence includes mechanistic experiments and small-scale human studies, the results of which are inconsistent. They do not confirm the predictable reversal of graying of hair in all individuals. [1]
Understanding the Greyverse requires distinguishing between the specific peptide, the mixture supplied by the manufacturer, and the ready-to-use formulation intended for application to the scalp. It is also necessary to separate the laboratory signals related to pigmentation from the visible and lasting restoration of hair color. This approach prevents presenting an interesting biological hypothesis as a commonly validated treatment method.
What is Greyverse? Names, synonyms and identity
The question does not simply come down to whether the ingredient is related to the biology of pigmentation. What is more important is determining whether a particular chemical can be linked to the material used in a specific experiment, and then to the finished product. Any such transition introduces additional uncertainty. The supplier’s information helps to understand the intended composition, but analytical identity and the actual content of the retail product are separate issues. This distinction also prevents the study history of the ingredient from being interpreted as a guarantee of product efficacy.
Graying of hair is a visible characteristic influenced by many processes. The presence of a peptide associated with pigmentation does not mean that every graying has the same cause or that every hair follicle has retained the ability to reproduce pigment. Therefore, it is more accurate to describe the Greyverse as a proposed cosmetic approach to pigmentation than as a commonly confirmed method for reversing graying.
Trade name and peptide name
Greyverse is a trade name, while palmitoyl tetrapeptide-20 amide is a peptide component listed in the current INCI declaration. In previous publications, the material under study was often referred to by the abbreviations PTP20 or PT-20. A reliable comparison should preserve the original nomenclature and take into account the formulation preparation methods, rather than assuming, without explanation, that all products use the same formulation.[1][2]
The trade name may include the material from the supplier, but it does not provide the full chemical specification. The peptide sequence, the terminal group chemistry, the anti-ion charge, the content of the substance, and the analytical identity remain important. Consumer products containing this ingredient may also contain other active substances and a different delivery system.
What does the term „alpha-MSH biomorpher” mean?
The term „biomimetic” means an attempt to mimic selected properties of a biological signal, rather than a full molecular and functional equivalence. Natural melanocortin signaling operates within a broader network of receptors, dye-producing cells, adjacent hair follicle cells, and local regulatory conditions. A short modified peptide can replicate one measured response in the laboratory while simultaneously differing from the natural hormone in terms of affinity, stability, selectivity, or distribution. These differences cannot be determined by descriptive marketing terminology.
A useful assessment should determine which test showed the claimed similarity. Colorations related to receptors, changes in gene expression, measurements of melanin, and pigmentation of new hair strands constitute further, distinct types of evidence. A positive result at an earlier stage does not mean that later effects must occur. The manufacturer’s statements should be best treated as an explanation of the design assumptions, unless they can be independently linked to a documented experimental result.
The manufacturer describes the peptide as a biomimetic of the alpha-melanotropic hormone, i.e., α-MSH. This means designing the compound to replicate selected aspects of pigment signaling. It does not mean that the compound is the full-length α-MSH or a natural hormone preparation.[1]
This term should be associated with experimental evidence. The proposed interaction with the receptor, the subsequent change in gene expression, and the visible darkening of growing hair are separate results. They require different measurements and allow different conclusions to be drawn.
How is Greyverse classified? Peptide, protein, mixture or other substance?
The classification also helps distinguish a cosmetic ingredient from a drug or a physiological hormone. The presence of a modified peptide does not confirm a pharmaceutical indication, and the INCI declaration describes the identity of the cosmetic ingredient, not the clinical benefit. The formulation can be correctly identified without conducting a controlled study demonstrating permanent restoration of pigmentation.
The molecular description of a peptide should not be confused with its biological availability. Even if a compound has a known sequence, it is not known what portion of it remains intact after being introduced into the lotion and what portion reaches the hair follicle environment. Chemical identification is an essential starting point for studying the mechanism, but it does not replace the measurements of substance delivery.
The active ingredient mentioned is a short modified peptide, whereas Greyverse in the form supplied by the manufacturer is a mixture. „Tetrapeptide” means four amino acid residues. „Palmitoyl” indicates a modification related to lipids, and „amide” indicates the chemistry of the terminal group. These elements of the name are important when comparing the tested molecule with another substance with a similar name. [1]
This component is not a large protein, a collection of all the peptides associated with hair growth, nor is it synonymous with any melanocortin agonist. Research on another agonist cannot be attributed to Greyverse simply because both compounds are discussed in the context of pigment biology.
| Name or material | What identifies | What does it not confirm |
|---|---|---|
| Greyverse | Commercial mixture of cosmetic ingredients | Full specifications of each retail product |
| Palmitoyl tetrapeptide-20 amide | Specified modified peptide component | The quantities reaching the target in the hair follicle |
| PTP20 or PT-20 in the publication | The abbreviation used by the authors for the research material | Automatic equivalence of formulations used in studies |
| Ready-to-use lotion for the scalp | The complete formulation | The effect attributed to the peptide itself without appropriate controls |
This classification also explains why the percentage values in formulas require interpretation. The percentage content of the delivered mixture does not necessarily correspond to the same content of the pure peptide. Comparisons require knowledge of the calculation basis for the concentration and the actual content of the peptide.
The structure and composition of Greyverse – what has been established?
The composition description should distinguish qualitative identification from quantitative characterization. The list of ingredients specifies what is declared as present, whereas the analytical designation can estimate the amount of the specified substance. Chromatographic, mass spectrometry, and appropriate sample patterns can help confirm the examined peptide, but the analytical method must allow differentiation of the related molecular forms. The percentage values given for the entire delivered mixture should not be converted into the content of pure peptide without additional data.
Distinguishing between a palmitoylated peptide and an unmodified tetrapeptide is important because lipid modification can affect solubility, interactions with formulation components, and interactions with biological barriers. The terminal amide group may also be important for accurate molecular identity. None of these characteristics alone does not prove that the compound reaches the melanocytes at an effective concentration. Storage and application stability must be considered in conjunction with penetration and local retention of the substance.
In comparative studies, researchers should document the exact chemical form of the peptide, analytical confirmation, consistency between batches, the formulation basis, and the calculation basis used in the methods. These details help determine whether the various published results actually refer to the same intervention or merely use the known trade name.
The current public description of the composition lists glycerin, water, and palmitoyl tetrapeptide-20 amide. A 2018 publication describes the synthesis and analytical characterization of the PTP20 formulation used. However, the product label itself does not provide confirmation of the sequence for a specific batch nor does it indicate that the commercial formulation corresponds to the material from this study.[1][2]
The literature on melanocortins indicates His–Phe–Arg–Trp as an important motif activating receptors in natural melanocortin peptides. Experiments with changes in this motif show that small differences in sequence can alter receptor responses. This provides a useful context for designing biomimetics, but should not replace the Greyverse identity certificate.[3]
Therefore, in this review, an unverified full structural formula and molecular mass were not assigned to all products sold under this trade name. The justified approach is to maintain the current manufacturer’s ingredient declaration and distinguish it from the exact chemical material described in the individual publications.
A reliable comparison of the materials would require batch documentation including peptide content, chromatographic profile, identity testing, end group and stability in the intended formulation. The carrier and other ingredients are important because the biological system interacts with the entire preparation, not just the name on the label.
Research on Greyverse – evidence in humans, animals and in the laboratory
The available literature is particularly interesting because it includes results indicating different directions. The mechanistic study provides a basis for analyzing the impact on pigmentation, while the case report suggests a possible response under uncontrolled conditions. A small series of cases presents different observations in which most participants did not show improvement according to external photographic assessment. The review of the evidence should consider all three sources, rather than choosing only the most favorable result.
When evaluating studies in humans, it is important to distinguish the population being studied, the exposure to the product, the comparison group, the assessment method, and the duration of the study. Without a randomized comparison with the background of changes occurring during use, it is not possible to reliably separate it from natural variability, concurrent use of other products, cosmetic coloring, or the expectations of observers. These limitations do not invalidate the recorded observations, but they narrow the conclusions that can be drawn from them.
Mechanistic study and preliminary study in humans from 2018
The laboratory and preliminary part concerning humans should be treated as separate elements. The results from cells or isolated hair follicles may support the biological activity related to the research objective, whereas the observations of volunteers relate to what happened with a specific application method and measurement schedule. The relationship between these results remains speculative until researchers directly establish that the measured biological response explains the observed pigmentary effect.
The group of 15 men is also too small to reliably describe the frequency of responses across the population. Premature graying may differ in cause from graying that occurs later, and the result obtained in one selected group should not be generalized to all age groups and hair types. The marker measured in the hair extracted from the follicles is a valuable endpoint of the study, but it should not be presented as a validated estimate of restoring hair color across the entire scalp.
Almeida Scalvino and colleagues studied PTP20 in cellular systems using isolated human hair and also conducted a preliminary study involving 15 men with premature graying. Responses related to pigmentation were reported and markers in the hair collected after three months were evaluated. The results support the biological rationale, but measurements of resident markers are not equivalent to a large controlled study demonstrating visible restoration of pigmentation. Authors affiliated with industry participated in the studies. [2]
Positive case description
The reported high percentage value requires careful wording. It describes the observation of one participant over a specific period, rather than the average improvement in the therapeutic group. The simultaneous use of oral supplements makes it impossible to unequivocally attribute the observed change to the Greyverse-containing local formulation. Without a control group or a control participant, it is also impossible to quantify the impact of other factors that change over time.
Case reports are valuable when they document an unusual outcome with sufficient clinical detail. Their main advantage is in generating hypotheses rather than establishing causality. In a balanced review, such a description should be presented alongside a less favorable series of cases and not used as evidence of a typical or expected outcome.
The case report indexed in 2023, published in the 2022 issue of the journal, concerned a 25-year-old woman in whom significant repigmentation of the hair was observed during the use of a formulation containing Greyverse. Oral supplements were also used. The authors reported a change of more than 90% gray hairs to black after five months, however, the observation concerned one person without a control group. This does not allow isolation of the peptide’s contribution or an estimate of how frequently similar results may occur. [4]
A small series of cases with less favorable outcomes
The value of 78.6% corresponds to the assessment in the study of the absence of clinical improvement, not to the frequency of adverse events or the universal probability of a lack of response. The difference between the participants' self-assessment and the review of the photographs also provides important information. The subjects being studied may notice subtle changes or interpret the appearance through the lens of expectations, while the assessor may apply more rigorous criteria or use photographs that do not reflect all the changes. None of the methods should be considered infallible.
Because the study was small and did not include a randomized control group, it cannot rule out benefits in any subgroup or with any formulation. However, it directly undermines claims that repigmentation is reliable. Negative or ambiguous observations should remain visible in educational materials, especially when positive user reports gain widespread publicity more often.
In a separate series, 14 people were observed for six months. At least two of the photo reviewers found that 78.6% participants did not show any clinical improvement, despite more positive self-evaluations. The authors concluded that their observations do not support the effectiveness. This is a significant contrast to the positive case report, although this series was also small and uncontrolled.[5]
What do the different categories of evidence mean?
These reports should not be combined as if they were comparable randomized studies. They differed in the population, the description of the formulations, the observation period, and the assessment of the results. A biomarker study, a single case, and a series of cases evaluated photographically can provide information on the same research question, but they do not allow one to calculate a reliable overall response rate.
For the purposes of this article, a separate efficacy study in live animals regarding exactly the same commercial Greyverse mixture has not been verified. Experiments with isolated human hair follicles are ex vivo studies, not animal treatment studies, nor are they supported by full clinical evidence of lasting benefit.
Action mechanisms studied in the context of Greyverse
The biological pathway from signaling associated with melanocortins to visible hair color involves many steps. Melanocytes must be present and functional, pigment production must occur, the pigment must be appropriately transported or incorporated into the growing hair, and the resulting change must be sufficiently large to be consistently observed. A change in the previous marker can occur without the completion of all subsequent steps.
Catalase and hydrogen peroxide measurements relate to oxidative stress biology, but do not provide a complete explanation of graying. Oxidative markers can change in parallel with many other cellular responses. A study observing the change in such a marker should present it as a measured biochemical result, rather than evidence of restoring the entire hair follicle to its previous biological state.
It is also important to distinguish between existing hair follicles and newly formed hair. Hair that has already grown beyond the follicle is intended for a different purpose than the incorporation of pigment during the formation of a new hair. Clinical studies should determine whether they measure emerging pigmented sections, the overall appearance in photographs, or color changes caused by the formulation itself. These endpoints cannot be used interchangeably.
The main research hypothesis concerns melanocortin signaling and the ability of pigment-producing cells in the hair follicles to maintain melanin production. A 2018 study analyzed markers related to MC1-R, responses to melanin, catalase, and hydrogen peroxide. These experiments indicate several related pathways worth further investigation, but do not prove that one of them explains all the causes of graying. [2]
Mechanistic claims should distinguish receptor activation from its quantity. The stronger receptor-related staining in itself does not quantify ligand binding or prove that similar exposure is achieved with conventional use of the product. Similarly, the change in oxidative stress measurement does not confirm the full restoration of the pigment-producing system of the hair follicle.
Receptor studies regarding specific sequences reinforce the need for caution. A related peptide may behave differently after being modified with an amino acid residue or a final modification, therefore the term „MSH-like” is not sufficient to transfer efficacy results between molecules. [3]
Strict demonstration of a causal relationship would require combining the verified identity of the material with the delivery of a hair follicle, a suitable biological response, and objectively measured pigmentation of the growing hair. Then it would be necessary to verify the durability of the effect. Failing to follow any of these steps leads to a claim broader than the measurements that support it.
Limitations of scientific evidence regarding the Greyverse
An additional limitation is the lack of a common, standardized endpoint in the cited reports. Not all studies quantify the same areas of the scalp, color characteristics, or the duration of the effect. Even if two studies report improvement, their percentages may not be suitable for direct comparison. A reliable overall estimate would require sufficiently similar methods and transparent results at the participant or group level.
Another uncertainty concerns the attribution of the effect of the active substance in the complete formulation. Solvents, moisturizers, preservatives, other cosmetic ingredients, and concurrent hair care practices can all influence both tolerance and appearance. Testing the finished formulation against a properly matched base would help identify the effect associated with the component. Comparing the two formulations could, however, provide information about the equivalence of the products.
Long-term results remain particularly important. The change in pigmentation observed during continuous application does not indicate that it will persist after it ends. The study of the durability of the effect should document the observation period, the growth of new hair, and factors such as color treatments. The current evidence should not be presented as confirmation of the permanent restoration of pigmentation.
Evidence in humans is limited in terms of numbers and does not provide a consistent, controlled estimate of the apparent benefits. The positive case report is burdened by the influence of concomitant supplementation, whereas the less favorable series of cases shows a discrepancy between the participants' perceptions and the external assessment. None of these projects can determine the effectiveness in all forms of graying. [4] [5]
Important unknowns include long-term durability, differences between populations, the role of ready-made formulations, and the relationship between molecular markers and apparent change. The absence of a response in one small study does not mean that no one can respond. However, a clear response in one person does not mean that it will occur in the majority.
Future studies would be more informative if they included randomization, appropriate controls with controls, blinded assessors, standardized scalp areas, and a previously defined endpoint for pigmentation. Hair dye and other concomitant interventions should be recorded. Reporting all included participants and those who withdrew from the study would help avoid an image based solely on selected individuals responding to the intervention.
Safety also requires a separate assessment. A small cosmetic report cannot provide reliable frequencies of rare reactions or confirm safety in every population. The identity of the ingredient, the tolerance of the formulation, and the intended application area remain important even when the proposed mechanism resembles a natural signaling pathway.
Frequently asked questions about Greyverse
1. Does Greyverse mean one defined substance?
Greyverse identifies a commercial mixture, not a pure isolated molecule. The current declaration lists the peptide alongside the carrier ingredients. [1] To compare the evidence, one needs to know the exact version and the finished formulation. The similarity of the trade name does not confirm the identical content of the peptide, chemical form, or exposure in the compared studies. A thorough comparison should indicate whether a supplier’s mixture, a laboratory-prepared peptide, or a finished retail product was used. Each of them may differ in peptide quantity and stability. The trade name is the starting point for searching for documents, not a substitute for chemical and formulation characteristics.
2. What do the available studies on Greyverse confirm?
They confirm the mechanistic rationale of the studies and preliminary, ambiguous observations in humans. The evidence includes laboratory endpoints, a positive single case report, and a series of cases whose authors did not confirm the apparent efficacy. [2] [5] The correct conclusion is that repigmentation remains a research question dependent on the product and population, rather than a predictable effect established for all. The studies do not provide a single overall probability value of pigment recovery by a given individual. Their designs, endpoints, and participant groups are too diverse to allow such interpretation. The responsible summary presents both positive and adverse observations together and indicates what has not yet been measured.
3. Is Greyverse the same as alpha-MSH?
No. The biomimetic component is not automatically a natural hormone. Common signaling concepts do not confirm identical receptor activity, distribution, stability, or clinical effects. [3] Evidence should pertain to the exact molecule being studied; therefore, the results of studies with other melanocortin substances cannot be used as direct confirmation of the Greyverse effect. Alpha-MSH functions within a physiological signaling context that the cosmetic analog may not replicate. The important question is whether this modified peptide exhibits a specific response at an achievable local exposure. Design similarity should not be interpreted as identical biological behavior.
4. Is Greyverse a white show?
The active ingredient mentioned is a short modified peptide, not a large protein. The delivered ingredient also contains a carrier system.[1] This distinction helps interpret labels and research materials, but the length of the chain alone does not tell much about whether the finished formulation achieves the exposure needed for a significant cosmetic effect. Being a peptide does not in itself confirm penetration through the skin, reaching the hair follicles, or tolerance. These properties depend on the molecular chemistry and the finished formulation. Classification is therefore useful for determining the identity of the ingredient, but insufficient for predicting the cosmetic outcome.
5. Are palmitoyl tetrapeptide-20 and palmitoyl tetrapeptide-20 amide alternative names?
The difference in nomenclature should be checked and not ignored. Scientific publications and current declarations do not always provide the same level of chemical detail. [2] [1] The absence of the word „amide” in the abbreviated research name alone does not prove that it refers to a different molecule. However, precise equivalence requires checking the methods or documentation provided by the supplier, rather than relying on editorial assumptions. The designation of the final amide group may be important for the precise chemical identity, even if the publication uses an abbreviation. Before identifying the names, researchers should familiarize themselves with the methods or analytical specifications. Otherwise, apparent replication may involve materials whose identity has not been demonstrated.
6. Does the formula 2% mean the content of 2% pure peptide?
Not necessarily, because the value can describe the commercial preparation of the ingredient. Comparisons of concentrations require a clear definition of the basis of calculation and the content of the peptide in the starting material. Without these data, two percentage values may refer to significantly different exposures. Authors’ wording should be respected and conversion of the percentage content of the formulation to the content of the pure active substance should be avoided without evidence. This distinction is important when comparing concentrations between publications and labels. The percentage of the supplier’s solution may include water and glycerin, whereas the percentage of the pure active substance refers to another basis of calculation. It should be provided instead of estimated values.
7. Does the positive case study evidence the efficacy of the ingredient?
No. The document records an observation that may serve as the basis for formulating a hypothesis. The published case study in the Greyverse also included another intervention, which makes it difficult to attribute the effect. [4] A controlled study is needed to distinguish the participation of the peptide from concomitant grooming, natural variability, and the influence of the assessment method. The case should therefore not be presented as the expected frequency of responses. The simultaneous use of supplements is an important limitation, because several types of exposure changed over the observation period. A single clear result does not also provide a basis for estimating the typical response or its absence. It is best to treat it as documented observation requiring controlled studies.
8. Why self-assessment and photographic assessment can give different results?
They use different methods and may be subject to different expectations. A small series of PT-20 showed more favorable self-evaluations than external evaluations based on photographs. [5] This difference suggests the use of both methods with clear definitions, rather than choosing the one that provides a stronger claim. Neither should be replaced without explanation by the other. Standardized photographs may still miss subtle changes, while self-evaluations can reflect expectations or different viewing conditions of hair. Consistency among independent, blinded evaluators would increase reliability. Evaluations of both favorable and unfavorable should be presented, rather than choosing one at the end of the study.
9. Does the increase in melanin levels in the laboratory indicate a visible darkening of the hair?
No. Biochemical or cellular measurement is not the same endpoint as the appearance of the scalp. The product would still have to reach the appropriate resident cells and induce a sufficiently large, sustained change affecting the growing hair. Mechanistic results therefore justify further research, whereas visible repigmentation requires its own standardized clinical measurement. The association between the pigmentation test and visible hair shaft requires evidence of local delivery and a sustained scalp response. Melanine growth under controlled laboratory conditions does not automatically translate into a change noticeable across the entire scalp.
10. Do Greyverse studies confirm the growth of new hair?
No. Pigmentation and hair growth are separate research results. A darker appearance does not indicate an increase in the number of follicles, hair density, or growth rate. The claim regarding growth would require measurements designed specifically for this purpose and appropriate observation, rather than relying on studies primarily focused on color. Hair growth studies would require their own endpoints, such as density, number of follicles, or growth measurements. The cited literature regarding the Greyverse focuses primarily on pigmentation. Combining claims about growth and color under one name may suggest the existence of evidence that has not been gathered.
11. Can a scalp examination confirm the effect on the beard or eyebrows?
Not automatically, because the anatomical area and exposure conditions are different. A formulation tested on the scalp may not have been evaluated near the eyes or on the face. Evidence for another area should specify its own population, tolerance, and pigmentary results, rather than assuming a uniform response across all hair types. Different application areas may have different hair growth cycles, skin characteristics, and exposure limitations. Products applied near the eyes also require special evaluation of the formulation's tolerance. Evidence from the scalp does not support efficacy or suitability for use in all other locations.
12. Is the proposed biological mechanism sufficient to explain every case of baldness?
No. The mechanism indicates one possible pathway, not all the causes of the observed change. Even the actual effect on pigmentation signaling may not overcome all limitations of a particular hair follicle. Clinical studies should therefore define the population and duration of graying to avoid biological reliability being confused with a universal response. The cause and duration of graying, as well as the preserved function of pigment cells, may influence the response, but the analyzed studies do not establish validated categories of responders. The claim that a specific group will definitely respond would be premature.
13. Do the evidence confirm the permanent restoration of pigmentation?
No. The analyzed reports do not confirm the persistent effect after the intervention has ended. The observation during product use answers a different question than the observation after its discontinuation. The claim of durability would require an appropriate period of observation and control of other color-changing factors. Therefore, the „observed improvement” should not be presented as a „permanent restoration of pigmentation.” A reliable assessment of durability should follow the new sections of hair after the application is completed and take into account dyeing and other practices affecting the color. The cited reports do not provide such long-term controlled observation. Temporary changes and permanent restoration of pigmentation must remain separate claims.
14. Do the results regarding one lot confirm the effect of another Greyverse product?
Not without significant formulation comparisons. The carrier ingredients, active substance content, stability and other components can influence both exposure and appearance. The common trade name helps to find the appropriate studies, but evidence regarding the finished product remains associated with that product unless equivalence is shown. Even when both products contain the same named ingredient, the vehicle can alter the stability and distribution of the peptide. Additional active ingredients can also make it difficult to attribute an effect. Controlled product evidence or a convincing formulation comparison are needed before results are transferred between lotions or serums.
15. Does the term „biomimetic” mean that the component does not cause irritation?
No. „Biomimetic” describes the design concept, not the full result of the safety assessment. The formulation contains more components than the highlighted peptide, and tolerance depends on the entire product and application conditions. Therefore, claims about safety should refer to relevant studies and their limitations, rather than infer a lack of response based on similarity to a natural biological signal. The inspiration from natural signaling does not preclude irritation, sensitization, or reactions to other components of the formulation. Small studies have particularly limited ability to detect rare events. Safety conclusions should correspond to the tested product, the group of participants, and the observation period.
16. How should hair photos be evaluated before and after using the product?
Attention should be paid to the lighting, the area of the scalp, the arrangement of the hair, the dyeing and the consistency of the conditions of the photo shoot. Otherwise, changes in the photographic exposure or styling can resemble a change in pigmentation. Evaluators who are blinded and previously determined scoring can improve the reliability, and a comparative group helps determine whether the observed difference is related to intervention and not independent variability. In long-term comparisons, the photographs should cover the same area of hair, lighting, angle, and image processing method. Recording the dyeing and the changes in the care routine helps avoid erroneous classification. If possible, independent blinded evaluation should complement the participants’ impressions.
17. What would stronger evidence of the effectiveness of Greyverse look like?
Stronger evidence would come from appropriately large controlled studies using a clearly identified formulation. They should present objective pigmentary results, participant experiences, adverse events, and the durability of the effect, along with uncertainty in the estimate. Independent replication of the results and transparent inclusion of nonrespondents would make the findings more useful than single photographs, selected user opinions, or mechanistic results alone.
Conclusions
The most important practical distinction for readers concerns the difference between the interesting research component and the confirmed clinical result. The Greyverse contains a peptide component identified by the supplier and has a biologically justified direction of research related to pigmentation. However, the cited human observations are limited, methodologically limited, and inconsistent. These facts are not contradictory: biological reliability warrants further research, while predictable consumer expectations require stronger evidence.
Greyverse combines a specific direction of cosmetic research with unresolved clinical questions. The mechanisms associated with the peptide can be scientifically investigated, but the visible results in humans remain preliminary and ambiguous. A thorough description separates molecular identity, formulation, measurements of pigmentation, and the durability of the effect, and includes adverse observations alongside positive ones.
Educational, medical and regulatory reservations
The article is of an exclusively scientific and educational nature. It does not constitute medical advice, diagnosis, treatment recommendations, or guarantees of cosmetic effects. Research on Greyverse and palmitoyl tetrapeptide-20 does not confirm reliable reversal of graying, permanent repigmentation, or treatment of diseases.
The referenced publications include laboratory studies, ex vivo biological material, a single case report and a small uncontrolled series of cases. The results cannot be automatically generalized to all individuals, products, and hair types. Safety depends on the complete composition of the formulation, individual sensitivity, and conditions of use. Sudden or alarming changes in hair and scalp require appropriate medical evaluation.
References
- Lucas Meyer Cosmetics. (2026, September 23). Greyverse [Ingredient product information]. https://www.lucasmeyercosmetics.com/en/Solutions/Products/2025/08/13/08/55/Greyverse
- Almeida Scalvino, S., Chapelle, A., Hajem, N., Lati, E., Gasser, P., Choulot, J. C., Michel, L., Hocquaux, M., Loing, E., Attia, J., & Wdzieczak-Bakala, J. (2018). Efficacy of an agonist of α-MSH, the palmitoyl tetrapeptide-20, in hair pigmentation. International Journal of Cosmetic Science, 40(5), 516–524. https://doi.org/10.1111/ics.12494
- Winget, M. D., Ericson, M. D., Freeman, K. T., & Haskell-Luevano, C. (2020). Single nucleotide polymorphisms in the melanocortin His-Phe-Arg-Trp sequences decrease tetrapeptide potency and efficacy. ACS Medicinal Chemistry Letters, 11(3), 272–277. https://doi.org/10.1021/acsmedchemlett.9b00198
- Chavan, D. (2022). Reversal of premature hair graying treated with a topical formulation containing α-melanocyte-stimulating hormone agonist (Greyverse solution 2%). International Journal of Trichology, 14(6), 207–209. https://doi.org/10.4103/ijt.ijt_85_22
- Melo, D. F., Tagliolatto, S., Studart, A. C., Gallo, B. F., Machado, C. J., Frattini, S. C., Weffort, F., & Cortez de Almeida, R. F. (2023). Is there a rationale for the use of an alpha-melanocyte-stimulating hormone analog to improve gray hair repigmentation? Skin Appendage Disorders, 9(1), 50–53. https://doi.org/10.1159/000527605